Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Story
test content
-
Featured News
Test
-
Story About Novartis Access to Healthcare
Test story page for non english content
-
Story
test story
-
Story
Test - Story - ContentSync - Translated content pulled from Repository
-
Story About Novartis
Test Content
Novartis announces the company’s financial results for the second quarter and first half of 2025.
-
Press release
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a… -
Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%… -
Press release
New Novartis ESC data highlights strength of cardiovascular portfolio
Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing… -
Press release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients… -
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s… -
Ad hoc release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March…
-
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s… -
Ad hoc release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March… -
Ad hoc release
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +12% USD) with core operating income1 up +21% (cc, +20% USD)Sales growth driven by continued strong performance from Kisqali (+… -
Ad hoc release
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™… -
Ad hoc release
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto… -
Ad hoc release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation…
-
Statement
Vas Narasimhan named to 2025 TIME100 Health list
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Story
test content
-
Story About Novartis Access to Healthcare
Test story page for non english content
-
Story
test story
-
Story
Test - Story - ContentSync - Translated content pulled from Repository
-
Story About Novartis
Test Content
Novartis announces the company’s financial results for the second quarter and first half of 2025.
-
Story About Novartis Access to Healthcare
test story content
test story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story content
Novartis Financial Results – Q2 2025
Novartis announces the company’s financial results for the second quarter and first half of 2025.
Novartis in Society Integrated Report 2024
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society.
Annual Report 2024
The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
